Valeant Expands Dermatology In Staged Deal With Meda
This article was originally published in The Pink Sheet Daily
Executive Summary
After announcing plans to acquire Elidel cream from Meda in April, Valeant announces the terms of the agreement and plans to acquire Xerese.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011
Of the $6.3 billion total raised, 32% was from China distributor Shanghai Pharmaceuticals' $1.99 billion IPO - not only Q2's biggest financing, but also the second-largest pharma IPO of all time. Six of the 26 completed mergers were done to gain access to emerging markets, most notably, Takeda's $13.7 billion buy of Nycomed, almost half of the total $27.9 billion spent on pharma acquisitions this quarter. Q2's largest alliance was Vertex's in-licensing of Alios BioPharma's preclinical HCV nucleotide analogues, a deal that could be worth up to $775 million in up fronts and development milestones.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011
Of the $6.3 billion total raised, 32% was from China distributor Shanghai Pharmaceuticals' $1.99 billion IPO - not only Q2's biggest financing, but also the second-largest pharma IPO of all time. Six of the 26 completed mergers were done to gain access to emerging markets, most notably, Takeda's $13.7 billion buy of Nycomed, almost half of the total $27.9 billion spent on pharma acquisitions this quarter. Q2's largest alliance was Vertex's in-licensing of Alios BioPharma's preclinical HCV nucleotide analogues, a deal that could be worth up to $775 million in up fronts and development milestones.
The Number One Question For Valeant: What Next?
Now that the hostile bid for Cephalon has fallen through, Valeant's CEO sees "no shortage of exciting opportunities" but says there's no hurry.